Immunotech Laboratories Attains Funding Partner on HIV Treatment Trials
Immunotech Laboratories, Inc. today announced the company has been in negotiations with an International Bio-Tech Partner in the HIV cure technology sector for joint advanced Research & Development and the partner has agreed to provide the necessary funding for the USA Clinical Trials phases to ultimately achieve FDA approval for the medicines.
A senior spokesperson for Immunotech further added, the terms while yet to be fully determined include some exclusive rights for the International partner for use and distribution of the vaccines in several countries where the equivalent of FDA approval is not required and can be distributed and administered labeled as an "Experimental Drug". This process will help accelerate the clinical trials results.
Pursuant to significantly positive results with its patient population targeting full blown AIDS patients, the company has completed numerous clinical contracts with Mexican hospitals to initiate a full blown effort of clinical trial protocol preparation for its HIV/AIDS Vaccine drug candidate. The successful outcome of these efforts will eventually provide the necessary regulatory means for its product's registration approval in the Republic of Mexico and eventually open a venue to most of the central and South American markets.
Source: Immunotech Laboratories Inc. via PR Newswire